Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 3, 2009, Pages 468-476

  Wu, Junli ^a   Wei, Jishu ^a   Meng, Kai ^a   Chen, Jianmin ^a   Gao, Wentao ^a   Zhang, Jingjing ^a   Xu, Zekuan ^a   Miao, Yi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

; dendritic cell; Cytotoxic T lymphocyte; Mucin4; Peptide; Vaccine

Indexed keywords

ANTIBODY; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MUCIN 4; PROTEIN P01204; UNCLASSIFIED DRUG; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; MUC4 PROTEIN, HUMAN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL STRAIN HCT116; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; EPITOPE MAPPING; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; MALE; MUCIN-4; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70350643679     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970902795203     Document Type: Article

References (39)

1. Porchet, N., Cong, N., Dufosse, J., et al. Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem. Biophys. Res. Commun. 1991, 175(2), 414-422.
2. Swartz, M.J., Batra, S.K., Varshney, G.C., et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol. 2002, 117(5), 791-796.
3. Andrianifahanana, M., Moniaux, N., Schmied, B.M., et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res. 2001, 7(12), 4033-4040.
4. Lopez-Ferrer, A., Alameda, F., Barranco, C., et al. MUC4 expression is increased in dysplastic cervical disorder. Hum. Pathol. 2001, 32(11), 1197-1202.
5. Botti, C., Seregni, E., Ménard, S. Two novel monoclonal antibodies against the MUC4 tandem repeat reacting with an antigen overexpressed by lung cancer. Int. J. Bio. Markers. 2000, 15(4), 312-320.
6. Packer, L,M., Williams, S,J., Callaghan, S., et al. Expression of the cell surface mucin gene family in adenocarcinomas. Int. J. Oncol. 2004, 25(4), 1119-1126.
7. Singh, A,P., Moniaux, N., Chauhan, S.C., et al. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004, 64(2), 622-630.
8. Pallavi, C., Singh, A.P., Surinder, K. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008, 22(4), 966-981.
9. Kwon, K., Ro, J., Singhal, N., et al. MUC4 expression in nonsmall cell lung carcinomas: Relationship to tumor histology and patient survival. Arch. Pathol. Lab. Med. 2007, 131(4), 593-598.
10. Chauhan, S., Singh, A., Ruiz, F., et al. Aberrant expression of MUC4 in ovarian carcinoma: Diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod. Pathol. 2006, 19(10), 1386-1394.
11. Alos, L., Lujan, B., Castillo, M., et al. Expression of membranebound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands. Am. J. Surg. Pathol. 2005, 29(6), 806-816.
12. Pardoll, D.M. Therapeutic vaccination for cancer. Clin Immunol, 2000, 95(1 Pt 2), 44-62.
13. Watts, C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol. 2004, 5, 685-692.
14. Francini, G., Scardino, A., Kosmatopoulos, K., et al. High- Affinity HLA-A*02.01 peptides from parathyroid hormonerelated protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. 2002, 169(9), 4840-4849.
15. Brossart, P., Heinrich, K., Stuhler, G., et al. Identification of HLAA2- Restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999, 93(12), 4309-4317.
16. Price-Schiavi, S., Perez, A., Barco, R., et al. Cloning and characterization of the 5' flanking region of the sialomucin complex/ rat Muc4 gene: Promoter activity in cultured cells. Biochem. J. 2000, 15(349), 641-649.
17. Panagiotopoulos, C., Qin, H., Tan, R., et al. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes. 2003, 52(11), 2647-2651.
18. Nijman, H.W., Houbiers, J.G., Vierboom, M.P., et al. Identification of peptide sequences that potentially trigger HLAA2.1- restricted cytotoxic T lymphocytes. Eur. J. Immunol. 1993, 23(6), 1215-1219.
19. Smith, S.G., Patel, P.M., Porte, J., et al. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin. Cancer Res. 2001, 7(12), 4253-4261.
20. Kim, G.G., Donnenberg, V.S., Donnenberg, A.D., et al. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: Comparisons to a 4 h 51Cr-release assay. J. Immunol. Methods. 2007, 325(1-2), 51-66.
21. Redchenko, I., Harrop, R., Ryan, M.G., et al. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology. 2006, 118(1), 50-57.
22. Escande, F., Lemaitre, L., Moniaux, N., et al. Genomic organization of MUC4 mucin gene. Towards the characterization of splice variants. Eur. J. Biochem. 2002, 269(15), 3637-3644.
23. Desseyn, J.L., Clavereau, I., Laine, A. Cloning, chromosomal localization and characterization of the murine mucin gene orthologous to human MUC4. Eur. J. Biochem. 2002, 269(13), 3150-3159.
24. Moniaux, N., Nollet, S., Porchet, N., et al. Complete sequence of the human mucin MUC4: A putative cell membrane-associated mucin. Biochem. J. 1999, 338(2), 325-333.
25. Seregni, E., Botti, C., Lombardo, C., et al. Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res. 1996, 16(4B), 2209-2213.
26. Komatsu, M., Yee, L., Carraway, K. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res. 1999, 59(9), 2229-2236.
27. Lee, K.T., Liu, T.S. Altered mucin gene expression in stone- containing intrahepatic bile ducts and cholangiocarcinomas. Dig. Dis. Sci. 2001, 46(10), 2166-2172.
28. Oka, Y., Tsuboi, A., Oji, Y., et al. WT1 peptide vaccine for the treatment of cancer. Curr. Opin. Immunol. 2008, 20(2), 211-220.
29. Tsuruma, T., Iwayama, Y., Ohmura, T., et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 2008, 10(6), 24.
30. Altuvia, Y., Margalit, H. A structure-based approach for prediction of MHC-binding peptides. Methods. 2004, 34(4), 454-459.
31. Consogno, G., Manici, S., Facchinetti, V., et al. Identification of immunodominant regions among promiscuous HLA-DRrestricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood. 2003, 101(3), 1038-1044.
32. Dong, H.L., Sui, Y.F., et al. Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method. World J. Gastroenterol. 2005, 11(2), 208-211.
33. Nielsen, M., Lundegaard, C., Worning, P., et al. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics. 2004, 20(9), 1388-1397.
34. Whiteside, T.L. Immunologic monitoring of clinical trials in patients with cancer: Technology versus common sense. Immunol. Invest. 2000 May, 29(2), 149-162
35. Correale, P., Micheli, L., Vecchio, M.T., et al. A parathyroidhormone- related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and lowdose IL-2. Br. J. Cancer. 2001, 85(11), 1722-1730.
36. Nagorsen, D., Thiel, E. HLA typing demands for peptide-based anti-cancer vaccine. Cancer Immunol. Immunother. 2008, 57(12), 1903-1910.
37. Eguchi, J., Hatano, M., Nishimura, F., et al. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006, 66(11), 5883-5891.
38. Mailliard, R.B., Wankowicz-Kalinska, A., Cai, Q., et al. alphatype- 1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004, 64, 5934-5937.
39. Herr, W., Ranieri, E., Olson, W., et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood. 2000, 96, 1857-1864.